0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
T-Cell Immunotherapy Market by Therapy Type, Cell Source, Target Antigens, Manufacturing Method, Patient Type, Indication, End-User - Global Forecast to 2030- Product Image
T-Cell Immunotherapy Market by Therapy Type, Cell Source, Target Antigens, Manufacturing Method, Patient Type, Indication, End-User - Global Forecast to 2030- Product Image
Sale

T-Cell Immunotherapy Market by Therapy Type, Cell Source, Target Antigens, Manufacturing Method, Patient Type, Indication, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 190 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4986070
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The T-Cell Immunotherapy Market grew from USD 7.34 billion in 2024 to USD 8.28 billion in 2025. It is expected to continue growing at a CAGR of 13.19%, reaching USD 15.44 billion by 2030.

Unveiling the Promise of T-Cell Immunotherapy

Developments in T-cell immunotherapy have ushered in a paradigm shift in the treatment of cancers and autoimmune disorders. This executive summary explores the key drivers, emerging trends, regulatory influences and strategic considerations shaping the market landscape. By examining advances in therapeutic modalities, shifts in manufacturing processes and the evolving reimbursement environment, stakeholders can gain a comprehensive view of the opportunities and challenges that lie ahead.

This summary synthesizes insights from in-depth analysis of therapy types, cell sources, antigen targets, patient segments and end-user categories. It also evaluates regional dynamics across the Americas, Europe, the Middle East & Africa and Asia-Pacific, while addressing the potential impact of newly enacted tariffs. Through this holistic approach, industry leaders and decision makers will be equipped with actionable intelligence to inform investment choices, partnership strategies and product development roadmaps.

Underpinned by rigorous research methodologies and expert interviews, the report distills complex data into accessible findings, enabling executives to prioritize initiatives that will drive innovation, optimize resource allocation and enhance patient outcomes.

Strategic Shifts Fueling a New Therapeutic Era

Breakthroughs in gene editing technologies, coupled with refined cell engineering techniques, have accelerated the development of CAR-T, TCR and TIL therapies. Advances in autologous manufacturing have reduced time to infusion, while innovations in allogeneic platforms promise to address scalability and cost constraints. Regulatory agencies are increasingly adopting adaptive review pathways, enabling faster approval of novel constructs and combination regimens.

At the same time, the integration of automated ex vivo processing systems is enhancing reproducibility and lowering contamination risks. Alternative in vivo delivery approaches are gaining traction for applications beyond oncology, including autoimmune and infectious diseases. These transformative shifts are fostering collaborations across biotech, academic centers and large pharmaceutical firms, creating an ecosystem that drives continuous innovation and market expansion.

Data analytics and machine learning tools are further refining patient stratification and optimizing antigen targeting, leading to enhanced safety profiles and prolonged treatment durability. As cross-sector partnerships proliferate, the convergence of digital health, precision medicine and cell therapy is setting the stage for the next therapeutic revolution.

Navigating the 2025 U.S. Tariff Landscape

With the implementation of new tariff measures in 2025, stakeholders face a recalibrated cost structure for imported raw materials and equipment. Cell therapy manufacturing heavily relies on specialized reagents and bioreactor components that are now subject to increased duties, translating into higher production expenses and potential delays in supply chain flows.

To mitigate these pressures, companies are diversifying procurement channels and negotiating long-term supply contracts with domestic producers. Some are exploring in-house reagent synthesis and localized manufacturing hubs to avoid import surcharges. Additionally, the recalibrated tariff environment is prompting strategic realignments in pricing and reimbursement negotiations, as firms balance margin preservation with patient access mandates.

Global partners are reevaluating collaboration models, with several organizations onshoring key operations to maintain continuity. These shifts underline the importance of supply chain resilience and proactive stakeholder engagement as defining elements of agility in a dynamically evolving policy landscape.

Deep Dive into Market Segmentation Dynamics

In analyzing the market by therapy type, the evaluation encompasses chimeric antigen receptor T-cell constructs, T-cell receptor based approaches and tumor infiltrating lymphocyte interventions. The study of cell source distinguishes between donor-derived allogeneic cells and patient-specific autologous cells, highlighting their respective advantages in scalability and individualized treatment efficacy. Antigen targeting considerations further refine this view, covering therapies directed at B-cell maturation antigen, CD19 and CD22 to address distinct disease profiles.

Manufacturing methodology is examined through the lens of both ex vivo processing pipelines and emerging in vivo modulation techniques, illuminating how production choices influence clinical timelines and cost parameters. Patient stratification spans adult and pediatric cohorts, recognizing the divergent safety profiles and therapeutic thresholds inherent to each group. The analysis of indications extends across autoimmune diseases, encapsulating lupus and rheumatoid arthritis, hematological malignancies with subcategories in leukemia, lymphoma and myeloma, and solid tumors including neoplasms of the brain and central nervous system, liver cancer and melanoma.

Finally, end-user segmentation evaluates deployment across cancer research institutes, hospitals and specialty clinics offering targeted T-cell treatments. This multifaceted segmentation framework provides a granular understanding of market adoption patterns and unmet needs, guiding strategic investments and product development pathways.

Regional Footprints Shaping Market Growth

In the Americas, robust research infrastructure and favorable reimbursement frameworks have propelled rapid adoption of T-cell therapies, with leading centers of excellence driving clinical trial enrollment and commercialization efforts. However, complex regulatory pathways and fragmented payer systems continue to challenge consistent market penetration across diverse healthcare jurisdictions.

Across Europe, the Middle East and Africa, harmonized regulatory initiatives and collaborative consortium models have fostered cross-border research and pooled procurement strategies, though disparities in healthcare budgets and access to specialized facilities can impede uniform uptake. In the Asia-Pacific region, emerging hubs in China, India and Australia are witnessing accelerated investment in cell therapy research and manufacturing capacity, supported by government incentives and public-private partnerships, while infrastructure development and workforce training remain critical for sustained growth.

Leading Innovators Driving the Field Forward

Industry leaders are driving innovation through expansive clinical pipelines, strategic acquisitions and technology partnerships. One prominent organization has established a robust portfolio of CAR-T constructs targeting both hematological and solid tumor antigens, while another has focused on advancing allogeneic platforms to enable off-the-shelf solutions. Collaborative agreements between biotech firms and large pharmaceutical companies are accelerating late-stage trials and expanding geographic reach.

Key innovators are also investing in manufacturing scale-up, deploying automated bioreactor systems and integrated quality control analytics to streamline production. Some are pioneering novel gene editing tools to enhance safety profiles and prolong therapeutic persistence. This competitive landscape underscores the importance of differentiation through product efficacy, cost efficiency and strategic alignments with academic institutions and contract manufacturing organizations.

Actionable Strategies for Industry Stakeholders

Leaders should prioritize diversification of therapeutic portfolios by balancing investments in established CAR-T constructs with emerging TCR and TIL modalities to capture a broad range of indications and patient populations. Expanding manufacturing capacity through partnerships or in-house facility development can mitigate supply bottlenecks and reduce exposure to tariff fluctuations. Engaging proactively with regulatory agencies to secure breakthrough designations and align on real-world evidence requirements will expedite time to market.

Further, forging alliances with payers and health technology assessment bodies can support value-based pricing models that enhance patient access while ensuring sustainable margins. Investing in digital platforms for patient monitoring and outcome data collection will strengthen post-launch evidence generation and inform iterative product improvements. A coordinated approach to global supply chain resilience, coupled with targeted marketing strategies for adult and pediatric segments, will position organizations to capitalize on evolving market dynamics.

Rigorous Methodology Underpinning Insights

The research is grounded in a comprehensive review of scientific literature, patent databases and regulatory filings to map the evolution of T-cell immunotherapy technologies and market entry pathways. Primary interviews were conducted with leading clinical investigators, industry executives and regulatory experts to capture nuanced perspectives on development challenges and adoption barriers. Secondary data from company reports, conference proceedings and peer-reviewed journals were triangulated to validate emerging trends.

A structured framework guided the segmentation and regional analyses, ensuring consistency across therapy types, cell sources, antigen targets, patient demographics and end-user categories. Qualitative insights were complemented by scenario modeling to assess the potential impact of tariff changes and pricing pressures. Quality control measures, including peer reviews and data audits, were implemented to uphold the integrity and reliability of the findings.

Synthesizing Insights for Future Direction

This synthesis distills critical insights into the transformative forces reshaping T-cell immunotherapy, from technological breakthroughs to policy influences and market segmentation nuances. By reconciling the implications of 2025 tariff adjustments with regional growth trajectories, strategic investment horizons and competitive positioning become more clearly defined. The interplay between therapy modalities, manufacturing methodologies and patient cohorts underscores a market characterized by both complexity and opportunity.

Moving forward, stakeholders can leverage the articulated recommendations and granular segmentation analysis to refine development roadmaps, advance commercialization efforts and optimize resource allocation. The path ahead will require adaptive strategies that integrate regulatory foresight, supply chain resilience and robust evidence generation to translate scientific potential into clinical and commercial successes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Type
    • CAR-T Therapy
    • TCR Therapy
    • TIL Therapy
  • Cell Source
    • Allogeneic Cells
    • Autologous Cells
  • Target Antigens
    • BCMA Targeting
    • CD19 Targeting
    • CD22 Targeting
  • Manufacturing Method
    • Ex-Vivo
    • In-Vivo
  • Patient Type
    • Adult Patients
    • Pediatric Patients
  • Indication
    • Autoimmune Diseases
      • Lupus
      • Rheumatoid Arthritis
    • Hematological Malignancies
      • Leukemia
      • Lymphoma
      • Myeloma
    • Solid Tumors
      • Brain & Central Nervous System
      • Liver Cancer
      • Melanoma
  • End-User
    • Cancer Research Institutes
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Adaptimmune Therapeutics PLC
  • Alaunos Therapeutics, Inc.
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics PLC
  • BioNTech SE
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARGO Therapeutics, Inc.
  • CARsgen Therapeutics Holdings Limited
  • Cellectis SA
  • Celyad Oncology SA
  • Chimera Bioengineering
  • Dendreon Pharmaceuticals LLC
  • Eureka Therapeutics, Inc.
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Immatics N.V.
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • LAVA Therapeutics N.V.
  • Lyell Immunopharma, Inc.
  • NeoTX Therapeutics Ltd.
  • Novartis AG
  • Oxford Vacmedix UK Limited
  • Poseida Therapeutics, Inc.
  • Sana Biotechnology, Inc.
  • TheraVectys SA
  • TScan Therapeutics, Inc.
  • Xenetic Biosciences, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. T-Cell Immunotherapy Market, by Therapy Type
8.1. Introduction
8.2. CAR-T Therapy
8.3. TCR Therapy
8.4. TIL Therapy
9. T-Cell Immunotherapy Market, by Cell Source
9.1. Introduction
9.2. Allogeneic Cells
9.3. Autologous Cells
10. T-Cell Immunotherapy Market, by Target Antigens
10.1. Introduction
10.2. BCMA Targeting
10.3. CD19 Targeting
10.4. CD22 Targeting
11. T-Cell Immunotherapy Market, by Manufacturing Method
11.1. Introduction
11.2. Ex-Vivo
11.3. In-Vivo
12. T-Cell Immunotherapy Market, by Patient Type
12.1. Introduction
12.2. Adult Patients
12.3. Pediatric Patients
13. T-Cell Immunotherapy Market, by Indication
13.1. Introduction
13.2. Autoimmune Diseases
13.2.1. Lupus
13.2.2. Rheumatoid Arthritis
13.3. Hematological Malignancies
13.3.1. Leukemia
13.3.2. Lymphoma
13.3.3. Myeloma
13.4. Solid Tumors
13.4.1. Brain & Central Nervous System
13.4.2. Liver Cancer
13.4.3. Melanoma
14. T-Cell Immunotherapy Market, by End-User
14.1. Introduction
14.2. Cancer Research Institutes
14.3. Hospitals
14.4. Specialty Clinics
15. Americas T-Cell Immunotherapy Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific T-Cell Immunotherapy Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa T-Cell Immunotherapy Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Adaptimmune Therapeutics PLC
18.3.2. Alaunos Therapeutics, Inc.
18.3.3. Allogene Therapeutics, Inc.
18.3.4. Amgen Inc.
18.3.5. AstraZeneca PLC
18.3.6. Atara Biotherapeutics, Inc.
18.3.7. Autolus Therapeutics PLC
18.3.8. BioNTech SE
18.3.9. bluebird bio, Inc.
18.3.10. Bristol-Myers Squibb Company
18.3.11. CARGO Therapeutics, Inc.
18.3.12. CARsgen Therapeutics Holdings Limited
18.3.13. Cellectis SA
18.3.14. Celyad Oncology SA
18.3.15. Chimera Bioengineering
18.3.16. Dendreon Pharmaceuticals LLC
18.3.17. Eureka Therapeutics, Inc.
18.3.18. Fate Therapeutics, Inc.
18.3.19. Gilead Sciences, Inc.
18.3.20. Immatics N.V.
18.3.21. Innovative Cellular Therapeutics
18.3.22. Iovance Biotherapeutics, Inc.
18.3.23. Johnson & Johnson
18.3.24. LAVA Therapeutics N.V.
18.3.25. Lyell Immunopharma, Inc.
18.3.26. NeoTX Therapeutics Ltd.
18.3.27. Novartis AG
18.3.28. Oxford Vacmedix UK Limited
18.3.29. Poseida Therapeutics, Inc.
18.3.30. Sana Biotechnology, Inc.
18.3.31. TheraVectys SA
18.3.32. TScan Therapeutics, Inc.
18.3.33. Xenetic Biosciences, Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. T-CELL IMMUNOTHERAPY MARKET MULTI-CURRENCY
FIGURE 2. T-CELL IMMUNOTHERAPY MARKET MULTI-LANGUAGE
FIGURE 3. T-CELL IMMUNOTHERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2024 VS 2030 (%)
FIGURE 14. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. T-CELL IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ALLOGENEIC CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOLOGOUS CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BCMA TARGETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CD19 TARGETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CD22 TARGETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LUPUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 74. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 75. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 76. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 77. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 80. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 81. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 82. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 84. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 87. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 90. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 91. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 126. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 127. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 128. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 129. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 130. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 132. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 133. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 134. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 136. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 137. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 138. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 139. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 140. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 142. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 143. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 144. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 146. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 156. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 157. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 158. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 159. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 162. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 163. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 164. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 166. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 167. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 168. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 176. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 177. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 178. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 186. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 187. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 188. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 206. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 207. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 208. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 216. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 217. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 218. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 219. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 222. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 223. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 224. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 246. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 247. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 248. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 249. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 250. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 251. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 253. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 254. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 257. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 258. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 259. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 260. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 261. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 263. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 264. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 265. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 266. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 267. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 268. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 269. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 270. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 271. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 272. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 273. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 274. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 275. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 277. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 278. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 279. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 280. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 281. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 282. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 283. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 284. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 285. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 286. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 287. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 288. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 289. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 290. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 292. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 293. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 294. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 295. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 306. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 307. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 308. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 309. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 310. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 312. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 313. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 314. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 315. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 316. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 317. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 318. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 319. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 320. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 321. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 322. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 326. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 327. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2030 (USD MILLION)
TABLE 328. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2030 (USD MILLION)
TABLE 329. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 332. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 333. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 334. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 335. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 336. NORWAY T-CELL IMMUNO

Companies Mentioned

The companies profiled in this T-Cell Immunotherapy market report include:
  • Adaptimmune Therapeutics PLC
  • Alaunos Therapeutics, Inc.
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics PLC
  • BioNTech SE
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARGO Therapeutics, Inc.
  • CARsgen Therapeutics Holdings Limited
  • Cellectis SA
  • Celyad Oncology SA
  • Chimera Bioengineering
  • Dendreon Pharmaceuticals LLC
  • Eureka Therapeutics, Inc.
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Immatics N.V.
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • LAVA Therapeutics N.V.
  • Lyell Immunopharma, Inc.
  • NeoTX Therapeutics Ltd.
  • Novartis AG
  • Oxford Vacmedix UK Limited
  • Poseida Therapeutics, Inc.
  • Sana Biotechnology, Inc.
  • TheraVectys SA
  • TScan Therapeutics, Inc.
  • Xenetic Biosciences, Inc.

Methodology

Methodology DOWNLOAD NOW

Table Information

Report AttributeDetails
No. of Pages190
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.28 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.44 Billion
Compound Annual Growth Rate13.1%
Regions CoveredGlobal
No. of Companies Mentioned34

Related Topics

Related Reports

Cellular Immunotherapy Market by Type, Technology Type, Indication, Institution Category - Global Forecast to 2030 - Product Image

Cellular Immunotherapy Market by Type, Technology Type, Indication, Institution Category - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Cancer Immunotherapy Market by Therapy Type, Indication, Mechanism Of Action, Line Of Therapy, Route Of Administration, End User - Global Forecast to 2030 - Product Image

Cancer Immunotherapy Market by Therapy Type, Indication, Mechanism Of Action, Line Of Therapy, Route Of Administration, End User - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Immunotherapy Drugs - Global Strategic Business Report - Product Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
EUR$5,850USDGBP
Global Cell Based Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Cell Based Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 110 Pages
  • Global
From
EUR$4,750USDGBP
Cellular Immunotherapy Market Report 2025 - Product Image

Cellular Immunotherapy Market Report 2025

  • Report
  • 175 Pages
  • Global
From
EUR$4,490USDGBP

About the T Cell Immunotherapy Market

T Cell Immunotherapy is a type of immune disorder drug that works by harnessing the power of a patient's own immune system to fight disease. It involves the extraction of T cells from a patient's blood, which are then genetically modified to recognize and attack cancer cells. This modified T cell is then reintroduced into the patient's body, where it can recognize and destroy cancer cells. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. T Cell Immunotherapy has been shown to be effective in treating certain types of cancer, and is being studied for its potential to treat other types of cancer and immune disorders. It is also being studied for its potential to treat autoimmune diseases, such as rheumatoid arthritis and type 1 diabetes. Some companies in the T Cell Immunotherapy market include Novartis, Kite Pharma, Juno Therapeutics, and Celgene. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more